Plasma Fractionation Market worth US$ 52.64 billion by 2030 with a CAGR of 7.5%

Published Date: March 2024

The report "Plasma Fractionation Market, By Product Type (Albumin, Immunoglobulins, Coagulation factor concentrates, and Others), By Application (Neurology, Hematology, Immunology, Critical Care, and Others), By End User (Hospitals and Clinics, Clinical Research Laboratories, and Academic Institutes), and Region - Global Forecast to 2030" The Plasma Fractionation Market accounted for US$ 25.6 billion 2020 and is estimated to be US$ 52.64 billion by 2030 and is anticipated to register a CAGR of 7.5%. Rising incidence of immunologic disorders and growing use of immunoglobulin and alpha-1 antitrypsin are major factors driving growth of the plasma fractionation market. In addition, increasing awareness of diseases such as hemophilia and rising incidence of sudden spreading of viral diseases across the globe are some among the major factors to raise the stakes for plasma fractionation by diagnostic centers. This factor leads to large-scale protein purification and ultimately propelling growth of the plasma fractionation market. Innovation and development in cost effective plasmapheresis equipment’s by manufacturers and increasing number of hemophilic patients can create lucrative opportunity for players operating in the plasma fractionation market.

Key Highlights:

  • In December 2017, BioLife Plasma Services L. P. had files for FDA approval of a new plasma manufacturing facility in Covington, Georgia to support growing immunology franchise.

Key Market Insights from the report:          

The Plasma Fractionation Market accounted for US$ 25.6 billion 2020 and is estimated to be US$ 52.64 billion by 2030 and is anticipated to register a CAGR of 7.5%. The market report has been segmented on the basis of product type, application, end user, and region.

  • By product type, the immunoglobulins segment is accounted for major revenue share in 2018, since it reduces adverse effects and drug reactions.
  • By application, the neurology segment is accounted for major revenue share in 2018, owing to rising incidences of neurological disorders and increasing aging population.
  • By end-user, the hospitals and clinics segment is accounted for major revenue share in 2018. This is due to improving infrastructure and healthcare facilities provided by hospitals, along with increasing off-label (non-approved) use of plasma fractionated products in hospitals for excessive bleeding due to trauma and surgery.
  • By region, North America plasma fractionation market accounted for major revenue share of the plasma fractionation market and is further anticipated to maintain its dominance over the forecast period. Due to increasing use of immunoglobulins in neurological diseases, and availability of appropriate healthcare infrastructure in the countries of the North America region. Europe plasma fractionation market accounted for second-highest market share, in 2018. This is due to increasing use of plasma fractioned in neurological diseases, in treatment hemophilic patients, and increasing use of prophylaxis treatments for diagnosed patients in this region. Asia Pacific plasma fractionation market is expected to grow at the highest rate during the forecast period owing to high expenditure for development of proper healthcare infrastructure by governments of countries in the region.

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on " Plasma Fractionation Market”, By Product Type (Albumin, Immunoglobulins, Coagulation factor concentrates, and Others), By Application (Neurology, Hematology, Immunology, Critical Care, and Others), By End User (Hospitals and Clinics, Clinical Research Laboratories, and Academic Institutes), and By Region (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa)- forecast till 2029

The prominent player operating in the plasma fractionation market includes CSL Plasma, Inc., Grifols S.A., BioLife Plasma Services L. P., Octapharma Plasma, Inc., Kedrion S.p.A, Bio Product Laboratory Ltd., LFB S.A., Biotest Pharmaceuticals Corporation, Japan Blood Products Organization, and China Biologic Products Holdings, Inc.

About Prophecy Market Insights

Prophecy Market Insights is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business.

Contact Us:

Sales

Prophecy Market Insights

Email- [email protected]

Buy Now
Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Custmoized Your Report
Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Request for Discount
Reliability and Reputation

Quick contact

IND: +91 777 504 9802
US: +1 860 531 2574

Trusted By

Created billion dollars of revenue impact with more than 200+ clients

View All Our Clients